Comparative Pharmacology
Head-to-head clinical analysis: GOCOVRI versus INGREZZA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GOCOVRI versus INGREZZA.
GOCOVRI vs INGREZZA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
GOCOVRI (amantadine) is an NMDA receptor antagonist that modulates glutamate-mediated excitotoxicity and increases dopamine release by inhibiting the vesicular monoamine transporter 2 (VMAT2) and potentiating dopaminergic function. It also has anticholinergic properties.
Vesicular monoamine transporter 2 (VMAT2) inhibitor; reduces presynaptic dopamine release.
Initial: 68.5 mg orally once daily at bedtime for 1 week; then increase to 137 mg once daily.
80 mg orally once daily; may titrate from 40 mg once daily for 7 days to reduce nausea.
None Documented
None Documented
The terminal elimination half-life is approximately 60–70 hours in healthy subjects, which supports once-daily dosing. Half-life may be prolonged in renal impairment.
Terminal elimination half-life of deutetrabenazine is 9-10 hours; clinical context: supports twice-daily dosing.
Renal excretion accounts for approximately 80% of elimination, with about 60% as unchanged drug and 20% as metabolites. Fecal excretion is minimal (<5%).
Approximately 60% renal (as unchanged drug and metabolites) and 30% fecal.
Category C
Category C
VMAT2 Inhibitor
VMAT2 Inhibitor